Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) released its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04, Zacks reports. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $1.47 on Friday. The firm has a fifty day simple moving average of $2.74 and a two-hundred day simple moving average of $3.19. Cellectis has a 52 week low of $1.25 and a 52 week high of $5.48. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The stock has a market capitalization of $147.50 million, a P/E ratio of -2.26 and a beta of 2.92.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CLLS. Weiss Ratings cut Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Robert W. Baird dropped their price target on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, September 15th. Wells Fargo & Company dropped their price target on Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 15th. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a report on Tuesday, September 15th. Finally, Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and reduced their price objective for the stock from $9.00 to $1.30 in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Cellectis presently has an average rating of “Hold” and an average price target of $5.46.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.